Related Experiment Video
Updated: Feb 20, 2026
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.4K
Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
Jun-Ichi Ohkubo1, Azusa Takahashi1, Shoji Ikezaki1
1Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health.
The Kurume Medical Journal
|October 24, 2017
Summary
Anaplastic thyroid carcinoma (ATC) with recurrence and metastasis showed a significant response to lenvatinib. However, severe side effects led to treatment discontinuation and rapid tumor regrowth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer with poor prognosis.
- Recurrence and distant metastasis significantly worsen patient outcomes.
- Molecular-targeted therapies offer new treatment avenues for advanced cancers.
Observation:
- A 91-year-old woman with recurrent ATC and lung metastases received lenvatinib.
- The patient experienced rapid tumor reduction in the neck and lungs.
- Severe side effects including hypertension and metabolic disturbances necessitated lenvatinib discontinuation.
Findings:
- Lenvatinib demonstrated significant efficacy in reducing tumor burden in recurrent ATC with metastasis.
- Treatment discontinuation due to adverse events led to rapid tumor progression.
- The case highlights the complex balance between efficacy and toxicity of targeted therapies.
Implications:
- Lenvatinib may be a viable treatment option for recurrent or metastatic ATC.
- Careful monitoring and management of side effects are crucial for lenvatinib therapy.
- Further research is needed to optimize the use of targeted agents in advanced thyroid cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
578
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
578
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K